Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS

Anti-CD19 chimeric antigen receptor (CAR) T cell therapy actually represents the standard of care for multiple relapsed or refractory primary mediastinal B-cell lymphoma (r/r PMBCL). Checkpoint inhibitors, such as pembrolizumab, appear to be a safe and effective treatment strategy for patients who a...

Descripción completa

Detalles Bibliográficos
Autores principales: Masucci, Chiara, Pepe, Sara, La Rocca, Ursula, Zullino, Veronica, De Propris, Maria Stefania, Barberi, Walter, Iori, Anna Paola, Martelli, Sabina, Ruberto, Franco, Martelli, Maurizio, Di Rocco, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310403/
https://www.ncbi.nlm.nih.gov/pubmed/37397390
http://dx.doi.org/10.3389/fonc.2023.1171031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310403/
https://www.ncbi.nlm.nih.gov/pubmed/37397390
http://dx.doi.org/10.3389/fonc.2023.1171031

Ejemplares similares